Shares of Agora, Inc. (API) surged 5.29% on Tuesday's intraday trading session, as the biopharmaceutical company announced the completion of its final FDA-required study for its lead asset CTx-1301, a potential new treatment for Attention Deficit Hyperactivity Disorder (ADHD).
The company reported that the food effect study on its highest 50mg dosage of CTx-1301 did not reveal any serious adverse events. This study aimed to determine if the medication can be taken with or without food, a crucial factor for ensuring optimal treatment outcomes.
With the completion of this final study, Agora is now targeting the submission of a New Drug Application (NDA) for CTx-1301 to the FDA by mid-2025. The company believes CTx-1301, utilizing its proprietary Precision Timed Release (PTR) drug delivery platform, has the potential to be the first true once-daily stimulant medication for treating ADHD throughout an entire active day.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.